Bluebird Beats Patent Case Over Blood Disease Therapies

By Theresa Schliep · May 19, 2025, 7:43 PM EDT

A Delaware federal judge has tossed a lawsuit against Bluebird Bio alleging two of its multimillion-dollar gene therapy treatments for blood disorders infringed patents held by San Rocco Therapeutics LLC, after...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

San Rocco Therapeutics, LLC v. Bluebird Bio, Inc., et al.

Case Number

Court

Delaware

Nature of Suit

Patent

Date Filed

October 21, 2021

Recent Articles By Theresa

May 08, 2025
Fed. Circ. Weighs If Expert's Testimony Justifies Spine IP Loss
May 05, 2025
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight
April 22, 2025
J&J Ends Trade Secrets Suit Against Now Deceased Ex-Exec
April 03, 2025
Senate Panel Advances Bills Tackling Drug Patents, Pricing
April 01, 2025
Two More Pharmacies Hit With Eli Lilly Weight Loss Drug Suits
March 14, 2025
Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar
March 13, 2025
Fed. Circ. Dings Antibody Patent App For Lacking Description
March 07, 2025
Apple Prevails In Watch Tech Patent Fight At Fed. Circ.
March 04, 2025
Moderna Faces MRNA Vax Patent Suits In Canada And Beyond
December 13, 2024
What's Left In $400M Skinny Label Row? A Lot, Court Says